Lexaria's DehydraTECH-Semaglutide Shows Promising Reduction in Side Effects Compared to Rybelsus®

Lexaria Bioscience Corp. has announced positive interim results from its Phase 1b study, GLP-1-H24-4, highlighting the efficacy of DehydraTECH-semaglutide in reducing side effects compared to the oral GLP-1 medication Rybelsus®. The study, conducted in Australia, shows a 36.5% reduction in overall adverse events (AEs) and a 43.5% decrease in gastrointestinal (GI) AEs with DehydraTECH-semaglutide, marking a significant advancement in patient safety and tolerability.

Richard Christopher, CEO of Lexaria, expressed optimism about the results, emphasizing the potential of DehydraTECH to outperform existing treatments by minimizing unwanted side effects. The study's findings are particularly relevant given the high incidence of AEs associated with current GLP-1 treatments, which often lead to premature discontinuation by patients.

Comparisons with Novo Nordisk's® STEP studies reveal that DehydraTECH-semaglutide could offer a safer alternative, with fewer patients experiencing AEs. The study also explores the effects of DehydraTECH-tirzepatide, noting a lower proportion of GI-related AEs compared to injectable tirzepatide, suggesting oral formulations may reduce side effects by up to half.

While the interim results are promising, Lexaria cautions that the full implications of these findings will only be clear upon completion of the study, expected by the end of 2025. The company remains committed to advancing its research, with the potential to revolutionize the treatment of conditions like obesity and type 2 diabetes by improving drug delivery and patient compliance.